Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)

NCT01221376 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+)

Interventions

DRUG: Imatinib Mesylate

Sponsor

Renato Melaragno